Letter
No access
Published Online: 16 August 2023

Letter to the Editor: The Cannabinoid Consumed Is Not Necessarily the One Expected: Recent Experience with Hexahydrocannabinol

Publication: Cannabis and Cannabinoid Research
Volume 9, Issue Number 5
First page of PDF

Get full access to this article

View all available purchase options and get full access to this article.

References

1. European Monitoring Centre for Drugs and Drug Addiction. Hexahydrocannabinol (HHC) and related substances: technical report. LU: Publications Office; 2023. Available from: https://data.europa.eu/doi/10.2810/852912 [Last accessed: July 6, 2023].
2. Golombek P, Müller M, Barthlott I, et al. Conversion of cannabidiol (CBD) into psychotropic cannabinoids including tetrahydrocannabinol (THC): A controversy in the scientific literature. Toxics 2020;8(2):41.
3. Ujváry I. Hexahydrocannabinol and closely related semi-synthetic cannabinoids: A comprehensive review. Drug Test Anal 2023 [Online ahead of print];
4. Arbouche N, Gheddar L, Guyon J, et al. Pediatric cannabis intoxication in France and Belgium: A 3-year retrospective study. Toxicol Anal Clin 2023;4481(1):1.
5. Spindle TR, Cone EJ, Kuntz D, et al. Urinary pharmacokinetic profile of cannabinoids following administration of vaporized and oral cannabidiol and vaporized CBD-dominant cannabis. J Anal Toxicol 2020;44(2):109–125.
Cite this article as: Guyon J, Paradis C, Titier K, Braganca C, Peyre A, Nardon A, Daveluy A, Molimard M, Labadie M, Castaing N (2023) Letter to the Editor: The cannabinoid consumed is not necessarily the one expected: recent experience with hexahydrocannabinol, Cannabis and Cannabinoid Research 9:5, e1459–e1461, DOI: 10.1089/can.2023.0154.

Information & Authors

Information

Published In

cover image Cannabis and Cannabinoid Research
Cannabis and Cannabinoid Research
Volume 9Issue Number 5October 2024
Pages: e1459 - e1461
PubMed: 37585622

History

Published in print: October 2024
Published online: 16 August 2023

Permissions

Request permissions for this article.

Topics

Authors

Affiliations

CHU de Bordeaux, Service de Pharmacologie Médicale, Bordeaux, France.
Université de Bordeaux, INSERM, BPH, U1219, Bordeaux, France.
Camille Paradis
CHU de Bordeaux, Centre Antipoison Nouvelle Aquitaine, Bordeaux, France.
Karine Titier
CHU de Bordeaux, Service de Pharmacologie Médicale, Bordeaux, France.
Coralie Braganca
CHU de Bordeaux, Centre Antipoison Nouvelle Aquitaine, Bordeaux, France.
Alexandre Peyre
CHU de Bordeaux, Service de Pharmacologie Médicale, Bordeaux, France.
Audrey Nardon
CHU de Bordeaux, Centre Antipoison Nouvelle Aquitaine, Bordeaux, France.
Amélie Daveluy
CHU de Bordeaux, Service de Pharmacologie Médicale, Bordeaux, France.
Mathieu Molimard
CHU de Bordeaux, Service de Pharmacologie Médicale, Bordeaux, France.
Université de Bordeaux, INSERM, BPH, U1219, Bordeaux, France.
Magali Labadie
CHU de Bordeaux, Centre Antipoison Nouvelle Aquitaine, Bordeaux, France.
Nadège Castaing
CHU de Bordeaux, Service de Pharmacologie Médicale, Bordeaux, France.

Notes

*
Address correspondence to: Joris Guyon, PharmD, PhD, CHU de Bordeaux, Service de Pharmacologie Médicale, Place Amélie Raba Leon, Bordeaux 33076, France, [email protected]

Metrics & Citations

Metrics

Citations

Export citation

Select the format you want to export the citations of this publication.

View Options

Access content

To read the fulltext, please use one of the options below to sign in or purchase access.

Society Access

If you are a member of a society that has access to this content please log in via your society website and then return to this publication.

Restore your content access

Enter your email address to restore your content access:

Note: This functionality works only for purchases done as a guest. If you already have an account, log in to access the content to which you are entitled.

View options

PDF/EPUB

View PDF/EPUB

Full Text

View Full Text

Figures

Tables

Media

Share

Share

Copy the content Link

Share on social media

Back to Top